Recent Updates
Recently added Catalysts

CVL-354

Phase 1

Healthy Participants | Small molecule | Other |AbbVie Inc.|Last Updated: Nov 25, 2024

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment73
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05138653A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy ParticipantsPHASE1 COMPLETED 73Oct 1, 2021Jan 1, 2023Nov 25, 2024 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
CVL-354DRUGOral solution/suspension
PlaceboDRUGPlacebo matched to CVL-354
Unlock Study Design Details